Status:
COMPLETED
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-69 years
Phase:
PHASE1
Brief Summary
This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin g...
Eligibility Criteria
Inclusion
- Type 1 diabetes mellitus (as diagnosed clinically) and treated with insulin for at least 12 months
- Subject is considered to be generally healthy, except for the underlying diabetes mellitus and related morbidity (such as well controlled hypertension and dyslipidaemia) based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator
- Body Mass Index (BMI) between 18.0 and 28.0 kg/m\^2 (both inclusive)
- Glycosylated haemoglobin (HbA1c) below or equal to 10.0 % based on central laboratory results
- Subject with a daily basal insulin requirement of between 0.2 IU/kg/day and 0.6 IU/kg/day will be allowed to participate in the trial. Current total daily treatment with insulin must be less than 1.2 U/kg/day
Exclusion
- Known or suspected allergy to trial product(s) or related products
- Subject who has participated in any other trials involving investigational products within 3 months preceding the start of dosing
- Subject who has donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01868529
Start Date
January 1 2008
End Date
June 1 2008
Last Update
September 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuss, Germany, 41460